Literature DB >> 1991975

Comparison of the effect of IL-2 and IL-6 on the lytic activity of purified human peripheral blood large granular lymphocytes.

M J Smyth1, J R Ortaldo.   

Abstract

The effects of IL-6 and IL-2 on highly purified, human peripheral blood large granular lymphocytes (LGL) were investigated and compared. IL-6 enhanced LGL NK activity in a dose-dependent manner against K562, however IL-2 was a more potent stimulus of LGL NK function. Neither IL-2 nor IL-6 increased LGL cytotoxic potential in a parallel estimation of heteroconjugated antibody (anti-CD16 x anti-nitrophenyl mAb)-dependent cytotoxicity against nitrophenyl-modified YAC. Unlike IL-2, IL-6 did not significantly induce LGL lymphokine-activated killer activity, LGL proliferation, or LGL lymphokine production. In particular, IL-6 did not stimulate detectable LGL IL-2 production or IL-2R modulation, and mAb to the p75 IL-2R had no effect on IL-6 induction of LGL NK activity. Therefore, in the absence of T cells, IL-6 provided an IL-2-independent signal to LGL that resulted in augmentation of their NK activity without stimulating their proliferation or other LGL functions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1991975

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  The transcriptional control of the perforin locus.

Authors:  Matthew E Pipkin; Anjana Rao; Mathias G Lichtenheld
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Authors:  Florian Anzengruber; Pinar Avci; Lucas Freitas de Freitas; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-06-11       Impact factor: 3.982

3.  Mycobacterial induction of activated killer cells: possible role of tyrosine kinase activity in interleukin-2 receptor alpha expression.

Authors:  D K Blanchard; S McMillen; S L Hoffman; J Y Djeu
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

4.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

5.  Induction of lymphokine-activated killer activity in mice by prothymosin alpha.

Authors:  C N Baxevanis; A D Gritzapis; G V Dedoussis; N G Papadopoulos; O Tsolas; M Papamichail
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

6.  Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low-dose interleukin-2.

Authors:  X Cao; W Zhang; S Gu; Y Yu; Q Tao; T Ye
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.